Dietary Fat Composition Affects Hepatic Angiogenesis and Lymphangiogenesis in Hepatitis C Virus Core Gene Transgenic Mice
Conclusion: This study revealed that diets rich in SFA and TFA, but not Chol, might stimulate hepatic angiogenesis/lymphangiogenesis mainly through the JNK-HIF1 α-VEGF-C axis. Our observations indicate the importance of dietary fat species for preventing hepatic tumorigenesis. (Source: Liver Cancer)
Source: Liver Cancer - September 16, 2022 Category: Cancer & Oncology Source Type: research
Dietary fat composition affects hepatic angiogenesis and lymphangiogenesis in HCV core gene transgenic mice
Conclusion: Th is study revealed that diets rich in SFA and TFA, but not Chol, might stimulate hepatic angiogenesis/lymphangiogenesis mainly through the JNK-HIF1α-VEGF-C axis. Our observations indicate an importance of dietary fat species for preventing hepatic tumorigenesis. (Source: Liver Cancer)
Source: Liver Cancer - September 16, 2022 Category: Cancer & Oncology Source Type: research
Tenofovir over Entecavir on Hepatocellular Carcinoma Prevention: Potential Mechanisms and Suitable Population
Not applicable for Letter according to Author Guidelines. (Source: Liver Cancer)
Source: Liver Cancer - September 8, 2022 Category: Cancer & Oncology Source Type: research
Letter regarding “Impact of Immune-Related Adverse Events on Efficacy of Immune Checkpoint Inhibitors in Patients with Advanced Hepatocellular Carcinoma”
Immunologic checkpoint inhibitors (ICIs) have demonstrated efficacy in a variety of malignancies. Despite impressive therapeutic benefits, ICIs may induce profound immune-related adverse events (irAEs). While the occurrence of irAEs may implicate improved T cell activity, whether irAEs predicts anti-tumor immune responses remains controversial. The paper by Kennedy Yao Yi Ng et al. adds to the evidence of the impact of irAEs in advanced hepatocellular carcinoma, which demonstrated that multi-system involvement of irAEs positively correlated with treatment responses and survival. We are, however, concerned about the groupin...
Source: Liver Cancer - August 31, 2022 Category: Cancer & Oncology Source Type: research
Phase 2 Study of the PD-1 Inhibitor Serplulimab Plus the Bevacizumab Biosimilar HLX04 in Patients with Previously Treated Advanced Hepatocellular Carcinoma
Conclusion: Serplulimab plus HLX04 showed a manageable safety profile and antitumor activity in patients with previously treated advanced HCC. (Source: Liver Cancer)
Source: Liver Cancer - August 30, 2022 Category: Cancer & Oncology Source Type: research
Hepatic Events and Viral Kinetics in Hepatocellular Carcinoma Patients Treated With Atezolizumab Plus Bevacizumab
Conclusions: Atezolizumab + bevacizumab had a similar hepatic safety profile in patients with and without HBV or HCV infection. Viral reactivation rates were similar between arms. Overall, these data support the use of atezolizumab + bevacizumab in patients with HCC and HBV or HCV infection without any special precaution. (Source: Liver Cancer)
Source: Liver Cancer - August 25, 2022 Category: Cancer & Oncology Source Type: research
First-line Systemic Therapies for Advanced Hepatocellular Carcinoma: A Systematic Review and Patient-Level Network Meta-Analysis
Conclusion: This NMA supports Anti-PD-(L)1/VEGF Ab as the first-line therapy for aHCC, and demonstrates a comparable benefit for tremelimumab-durvalumab which also ex tends to certain subgroups. Results of the subgroup analysis may guide treatment according to baseline characteristics, while pending further studies. (Source: Liver Cancer)
Source: Liver Cancer - August 23, 2022 Category: Cancer & Oncology Source Type: research
Hepatitis B Virus Treatment and Hepatocellular Carcinoma: Controversies and Approaches to Consensus
Background: Long-term therapy with nucleos(t)ide analogs (NAs) such as entecavir (ETV) and tenofovir disoproxil fumarate (TDF) favorably affects the incidence of hepatocellular carcinoma (HCC) on the basis of data from randomized or matched control studies. Recent data suggest a lower HCC incidence after 5 years of ETV or TDF therapy in chronic hepatitis B (CHB) patients, especially those with baseline cirrhosis.Summary: Three controversial issues remain to be resolved regarding hepatitis B virus (HBV) treatment and HCC. (1) The efficacy of antiviral treatment for the prevention of HCC is not established. The guidelines of...
Source: Liver Cancer - August 23, 2022 Category: Cancer & Oncology Source Type: research
Hepatitis B virus treatment and hepatocellular carcinoma - controversies and approaches to consensus
Background: Long-term therapy with nucleos(t)ide analogues (NAs) such as entecavir (ETV) and tenofovir disoproxil fumarate (TDF) favorably affects the incidence of hepatocellular carcinoma (HCC) on the basis of data from randomized or matched control studies. Recent data suggest a lower HCC incidence after 5 years of ETV or TDF therapy in chronic hepatitis B (CHB) patients, especially those with baseline cirrhosis.
Summary: Three controversial issues remain to be resolved regarding hepatitis B virus (HBV) treatment and HCC.
1) The efficacy of antiviral treatment for the prevention of HCC is not established. Guidelines of...
Source: Liver Cancer - August 23, 2022 Category: Cancer & Oncology Source Type: research
Immune checkpoint inhibitor-related pneumonia in unresectable hepatocellular carcinoma: Two fatal cases under atezolizumab plus bevacizumab
No abstract due to Letter. (Source: Liver Cancer)
Source: Liver Cancer - August 16, 2022 Category: Cancer & Oncology Source Type: research
Atezolizumab plus Bevacizumab Followed by Curative Conversion (ABC Conversion) in Patients with Unresectable, TACE-unsuitable Intermediate-stage Hepatocellular Carcinoma
N/A (Source: Liver Cancer)
Source: Liver Cancer - July 27, 2022 Category: Cancer & Oncology Source Type: research
Chinese Expert Consensus on Immunotherapy for Hepatocellular Carcinoma (2021 edition)
Background: Hepatocellular carcinoma (HCC) is one of the most common malignancies in China. Most HCC patients are firstly diagnosed at an advanced stage, and systemic treatments are the mainstay of treatment. Summary: In recent years, immune checkpoint inhibitors have made a breakthrough in the systemic treatment of middle-advanced HCC, breaking the single therapeutic pattern of molecular targeted agents. To better guide the clinical treatment for effective and safe use of immunotherapeutic drugs, the Chinese Association of Liver Cancer and Chinese Medical Doctor Association has gathered multidisciplinary experts and schol...
Source: Liver Cancer - July 20, 2022 Category: Cancer & Oncology Source Type: research
Response to the Article on Antibiotics and Immune Checkpoint Inhibitors by Lin et al.
(Source: Liver Cancer)
Source: Liver Cancer - July 13, 2022 Category: Cancer & Oncology Source Type: research
Response to Kong-Ying Lin, Shi-Chuan Tang, Cheung-Wu Zhang, Yong-Yi Zeng, Tian Yang
We thank Lin KY et al for their comments on our manuscript entitled “Use of antibiotics during immune checkpoint inhibitors associates with lower survival in hepatocellular carcinoma”.1 Several issues were raised in the letter including the start time for survival analysis, the details of survival time with Kaplan-Meier curve and definition of cancer-related dea th.
In the “Outcome definition” paragraph of our manuscript, it was mentioned that patients were observed from the start date of first immune checkpoint inhibitor as the index date till the occurrence of the outcome of interest or end of study. In the same...
Source: Liver Cancer - July 13, 2022 Category: Cancer & Oncology Source Type: research
Sulfatase-2 from Cancer Associated Fibroblasts: An Environmental Target for Hepatocellular Carcinoma?
Conclusion: SULF2 derived from CAFs modulates glypican-3/ β-catenin signalling but also the HCC immune TME, associated with tumour progression and therapy resistance via activation of the TAK1/IKKβ/NF-κB pathway. It is an attractive target for combination therapies for patients with HCC. (Source: Liver Cancer)
Source: Liver Cancer - July 13, 2022 Category: Cancer & Oncology Source Type: research